Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ocugen, Inc. filings on SEC EDGAR ↗
Ocugen, Inc. reported total assets of $108.1 million as of September 30, 2026, a significant increase from $43.5 million at the end of 2025, primarily driven by $59.6 million in new short-term investments. The company is currently advancing its Phase 3 trial for OCU400 and Phase 2/3 trial for OCU410ST while maintaining its status as a non-accelerated filer and smaller reporting company.
Ocugen reported Q3 2026 financial results, highlighting a cash position of $84.6 million with an expected runway into 2028. The company advanced its gene therapy pipeline, including the initiation of the Phase 3 ArMaDa3 trial for OCU410 and receiving provisional approval for OCU400 in The Bahamas.
Term
Q3 2026
“With three Phase 3 modifier gene therapy programs underway, Ocugen is executing against a clear strategy of advancing our pipeline and leveraging strategic partnerships to expand global reach and potentially bring our therapies to patients worldwide.”
Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen
“As we demonstrated in the third quarter, we remain focused on executing key clinical and regulatory milestones, expanding our commercial opportunities, and maintaining a disciplined approach as we advance toward the anticipated OCU400 Phase 3 topline data early next year.”
Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen